Assessing the impact of MSH3 and MSH6 polymorphisms on lung cancer risk in North Indian patients undergoing platinum chemotherapy through molecular dynamics simulation.
Humans
Lung Neoplasms
/ genetics
Male
Middle Aged
Female
Cisplatin
/ therapeutic use
Genetic Predisposition to Disease
MutS Homolog 3 Protein
/ genetics
DNA-Binding Proteins
/ genetics
Polymorphism, Single Nucleotide
Docetaxel
/ therapeutic use
India
/ epidemiology
Aged
Case-Control Studies
Genotype
Adult
Carboplatin
/ therapeutic use
Chemotherapy
Lung cancer
MSH3
MSH6
Overall survival
Polymorphism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 Jul 2024
13 Jul 2024
Historique:
received:
18
04
2024
accepted:
08
07
2024
medline:
14
7
2024
pubmed:
14
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
The present study investigated the relationship between MSH3 and MSH6 genes in lung cancer patients. Genotyping of lung cancer patients and healthy controls was performed. Odds ratio values were calculated and survival analysis performed. Patients with mutant genotype (TT) for MSH6 polymorphism have 1.5-fold risk for the development of lung cancer (p = 0.03). For non-smokers, the mutant-type genotype had a threefold increased risk of lung cancer (p = 0.01). Patients administered with docetaxel and carbo/cisplatin and carrying GT genotype for MSH6 polymorphism, patients reported a decrease in median survival time (4.9 vs 9.13 months). MSH3 and MSH6 polymorphisms are involved in modulating the risk towards lung cancer. MSH6 polymorphism is associated with high mortality rate for patients undergoing cisplatin and docetaxel chemotherapy.
Identifiants
pubmed: 39003369
doi: 10.1038/s41598-024-67090-x
pii: 10.1038/s41598-024-67090-x
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
MutS Homolog 3 Protein
0
DNA-Binding Proteins
0
MSH3 protein, human
0
G-T mismatch-binding protein
0
Docetaxel
15H5577CQD
Carboplatin
BG3F62OND5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16164Informations de copyright
© 2024. The Author(s).
Références
Ferlay, J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 primary cancers in 2018. Eur. J. Cancer 103, 356–387 (2018).
doi: 10.1016/j.ejca.2018.07.005
pubmed: 30100160
Beržinec, B. Epidemiológia, etiológia, diagnostika a skríning karcinómu pľúc. Onkológia (Bratislava). 1, 22–25 (2006).
Cassidy, A. et al. Family history and risk of lung cancer: Age-at-diagnosis in cases and first-degree relatives. Br. J. Cancer 95(9), 1288–1290 (2006).
doi: 10.1038/sj.bjc.6603386
pubmed: 17003779
pmcid: 2360569
Caja, F. et al. DNA mismatch repair gene variants in sporadic solid cancers. Int. J. Mol. Sci. 21(15), 5561 (2020).
doi: 10.3390/ijms21155561
pubmed: 32756484
pmcid: 7432688
Jang, J. H. et al. Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk. Carcinogenesis 33(4), 818–827 (2012).
doi: 10.1093/carcin/bgs028
pubmed: 22301281
pmcid: 3324443
Dylawerska, A. et al. Association of DNA repair genes polymorphisms and mutations with increased risk of head and neck cancer: A review. Med. Oncol. 34(12), 197 (2017).
doi: 10.1007/s12032-017-1057-4
pubmed: 29143133
pmcid: 5688183
Iyer, R. R. et al. DNA mismatch repair: Functions and mechanisms. Chem. Rev. 106(2), 302–323 (2006).
doi: 10.1021/cr0404794
pubmed: 16464007
Benachenhou, N. et al. High-resolution deletion mapping reveals frequent allelic losses at the DNA mismatch repair loci hMLH1 and hMSH3 in non-small cell lung cancer. Int. J. Cancer 77(2), 173–180 (1998).
doi: 10.1002/(SICI)1097-0215(19980717)77:2<173::AID-IJC1>3.0.CO;2-N
pubmed: 9650548
Surtees, J. A. & Alani, E. Mismatch repair factor MSH2-MSH3 binds and alters the conformation of branched DNA structures predicted to form during genetic recombination. J. Mol. Biol. 360(3), 523–536 (2006).
doi: 10.1016/j.jmb.2006.05.032
pubmed: 16781730
Hirata, H. et al. Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer. J. Urol. 179(5), 2020–2024 (2008).
doi: 10.1016/j.juro.2008.01.009
pubmed: 18355840
pmcid: 3940351
Miao, H. K. et al. MSH3 rs26279 polymorphism increases cancer risk: A meta-analysis. Int. J. Clin. Exp. Pathol. 8(9), 11060 (2015).
pubmed: 26617824
pmcid: 4637639
Nogueira, G. A. et al. Polymorphisms in DNA mismatch repair pathway genes predict toxicity and response to cisplatin chemoradiation in head and neck squamous cell carcinoma patients. Oncotarget 9(51), 29538 (2018).
doi: 10.18632/oncotarget.25268
pubmed: 30038702
pmcid: 6049861
Conde, J. et al. Association of common variants in mismatch repair genes and breast cancer susceptibility: A multigene study. BMC Cancer 9(1), 1–9 (2009).
doi: 10.1186/1471-2407-9-344
Liu, Y. et al. Correlation between polymorphisms in DNA mismatch repair genes and the risk of primary hepatocellular carcinoma for the Han population in northern China. Scand. J. Gastroenterol. 50(11), 1404–1410 (2015).
doi: 10.3109/00365521.2015.1045429
pubmed: 26027715
Xu, X. L. et al. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Genet. Mol. Res. 14(2), 3525–3530 (2015).
doi: 10.4238/2015.April.15.16
pubmed: 25966119
Singh, S., Singh, N. & Sharma, S. Genetic polymorphisms in the mismatch repair pathway (MMR) genes contribute to hematological and gastrointestinal toxicity in North Indian lung cancer patients treated with platinum-based chemotherapy. J. Biochem. Mol. Toxicol. 36(11), e23183 (2022).
doi: 10.1002/jbt.23183
pubmed: 35924411
Ray, A. K. et al. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery. Comput. Biol. Med. 142, 105183 (2022).
doi: 10.1016/j.compbiomed.2021.105183
pubmed: 34986429
Singh, S. et al. Genotyping, in silico screening and molecular dynamics simulation of SNPs of MGMT and ERCC1 gene in lung cancer patients treated with platinum-based doublet chemotherapy. J. Biomol. Struct. Dyn. https://doi.org/10.1080/07391102.2023.2261052 (2023).
doi: 10.1080/07391102.2023.2261052
pubmed: 38149858
Panda, S. K., Saxena, S. & Guruprasad, L. Homology modeling, docking and structure-based virtual screening for new inhibitor identification of Klebsiella pneumoniae heptosyltransferase-III. J. Biomol. Struct. Dyn. 38, 1887–1902 (2020).
doi: 10.1080/07391102.2019.1624296
pubmed: 31179839
Panda, S. K., Saxena, S., Gupta, P. S. S. & Rana, M. K. Inhibitors of Plasmepsin X Plasmodium falciparum: Structure-based pharmacophore generation and molecular dynamics simulation. J. Mol. Liq. 340, 116851 (2021).
doi: 10.1016/j.molliq.2021.116851
Bhattacharya, U., Panda, S. K., Gupta, P. S. S. & Rana, M. K. Inhibitors of Heptosyltransferase I to prevent heptose transfer against antibiotic resistance of E. coli: Energetics and stability analysis by DFT and molecular dynamics. J. Mol. Struct. 1253, 132258 (2022).
doi: 10.1016/j.molstruc.2021.132258
Sen Gupta, P. S., Biswal, S., Singha, D. & Rana, M. K. Binding insight of clinically oriented drug famotidine with the identified potential target of SARS-CoV-2. J. Biomol. Struct. Dyn. 39, 5327–5333 (2021).
doi: 10.1080/07391102.2020.1784795
pubmed: 32579065
Singh, S. et al. Polymorphisms in the MSH2 gene predict poor survival of North Indian lung cancer patients undergoing chemotherapy. Biomark. Med. 16(2), 69–82 (2022).
doi: 10.2217/bmm-2021-0565
Yadav, S. K. et al. Single nucleotide polymorphism of MSH3 gene alters head and neck squamous-cell carcinoma risk in North-India. Int. J. Cancer Res. 14(1), 27–31 (2018).
doi: 10.3923/ijcr.2018.27.31
Zelga, P. et al. Polymorphism of Gly39Glu (c. 116G> A) hMSH6 is associated with sporadic colorectal cancer development in the Polish population: Preliminary results. Adv. Clin. Exp. Med. 26(9), 1425–1429 (2017).
doi: 10.17219/acem/64877
pubmed: 29442465
Niazi, Y. et al. DNA repair gene polymorphisms and chromosomal aberrations in healthy, nonsmoking population. DNA Repair 101, 103079 (2021).
doi: 10.1016/j.dnarep.2021.103079
pubmed: 33676360
Smith, T. R. et al. Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis 29(11), 2132–2138 (2008).
doi: 10.1093/carcin/bgn193
pubmed: 18701435
pmcid: 2722862
Berndt, S. I. et al. Mismatch repair polymorphisms and the risk of colorectal cancer. Int. J. Cancer 120(7), 1548–1554 (2007).
doi: 10.1002/ijc.22510
pubmed: 17205513
Tulupova, E. et al. Do polymorphisms and haplotypes of mismatch repair genes modulate risk of sporadic colorectal cancer?. Mutat. Res. 648(1–2), 40–45 (2008).
doi: 10.1016/j.mrfmmm.2008.09.005
pubmed: 18851982
Vogelsang, M. et al. Aberrant methylation of the MSH3 promoter and distal enhancer in esophageal cancer patients exposed to first-hand tobacco smoke. J. Cancer Res. Clin. Oncol. 140(11), 1825–1833 (2014).
doi: 10.1007/s00432-014-1736-x
pubmed: 24934723
Vogelsang, M. et al. The cumulative effects of polymorphisms in the DNA mismatch repair genes and tobacco smoking in oesophageal cancer risk. PloS One 7(5), e36962 (2012).
doi: 10.1371/journal.pone.0036962
pubmed: 22623965
pmcid: 3356375
Carrera-Lasfuentes, P. et al. Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype. Oncotarget 8(22), 35848 (2017).
doi: 10.18632/oncotarget.16261
pubmed: 28415781
pmcid: 5482622
Nogueira, G. A. S. et al. Association between genetic polymorphisms in DNA mismatch repair-related genes with risk and prognosis of head and neck squamous cell carcinoma. Int. J. Cancer 137(4), 810–818 (2015).
doi: 10.1002/ijc.29435
pubmed: 25598504
Zanusso, C. et al. Impact of DNA repair gene polymorphisms on the risk of biochemical recurrence after radiotherapy and overall survival in prostate cancer. Oncotarget 8(14), 22863 (2017).
doi: 10.18632/oncotarget.15282
pubmed: 28206966
pmcid: 5410269
Takahashi, M. et al. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly (ADP-ribose) polymerase inhibitor. J. Biol. Chem. 286(14), 12157–12165 (2011).
doi: 10.1074/jbc.M110.198804
pubmed: 21285347
pmcid: 3069420